Files in this item
Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV-1 maturation inhibitor bevirimat
Item metadata
dc.contributor.author | Adamson, Catherine S | |
dc.contributor.author | Sakalian, M | |
dc.contributor.author | Salzwedel, K | |
dc.contributor.author | Freed, E.O. | |
dc.date.accessioned | 2010-11-23T10:23:14Z | |
dc.date.available | 2010-11-23T10:23:15Z | |
dc.date.issued | 2010-04 | |
dc.identifier | 482525 | |
dc.identifier | 55a5d03d-b17f-4d93-b8ef-50de95fe640a | |
dc.identifier | 77950929797 | |
dc.identifier | 000278330800001 | |
dc.identifier.citation | Adamson , C S , Sakalian , M , Salzwedel , K & Freed , E O 2010 , ' Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV-1 maturation inhibitor bevirimat ' , Retrovirology , vol. 7 , 36 . https://doi.org/10.1186/1742-4690-7-36 | en |
dc.identifier.issn | 1742-4690 | |
dc.identifier.other | standrews_research_output: 32688 | |
dc.identifier.other | ORCID: /0000-0001-7673-5212/work/60630450 | |
dc.identifier.uri | https://hdl.handle.net/10023/1439 | |
dc.description.abstract | Background: The maturation inhibitor bevirimat (BVM) potently inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking capsid-spacer peptide 1 (CA-SP1) cleavage. Recent clinical trials demonstrated that a significant proportion of HIV-1-infected patients do not respond to BVM. A patient’s failure to respond correlated with baseline polymorphisms at SP1 residues 6-8. Results: In this study, we demonstrate that varying levels of BVM resistance are associated with point mutations at these residues. BVM susceptibility was maintained by SP1-Q6A, -Q6H and -T8A mutations. However, an SP1-V7A mutation conferred high-level BVM resistance and SP1-V7M and T8Δ mutations conferred intermediate levels of BVM resistance. Conclusions: Future exploitation of the CA-SP1 cleavage site as an antiretroviral drug target will need to overcome the baseline variability in the SP1 region of Gag. | |
dc.format.extent | 8 | |
dc.format.extent | 2155363 | |
dc.language.iso | eng | |
dc.relation.ispartof | Retrovirology | en |
dc.subject | QR355 Virology | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject.lcc | QR355 | en |
dc.title | Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV-1 maturation inhibitor bevirimat | en |
dc.type | Journal article | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.contributor.institution | University of St Andrews. Biomedical Sciences Research Complex | en |
dc.identifier.doi | https://doi.org/10.1186/1742-4690-7-36 | |
dc.description.status | Peer reviewed | en |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=77950929797&partnerID=8YFLogxK | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.